Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Fumaric Acid Tegeline Injection, aimed at providing analgesia for patients on mechanical ventilation in intensive care [1] Company Summary - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist [1] - The product is set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 innovative opioid analgesic [1]

Investment Rating - The report continues to recommend the innovative drug and medical device industry chain, indicating a high level of investment interest in this sector [1][5]. Core Views - The report highlights the high prosperity in innovative drugs, suggesting potential value revaluation for companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [2][5]. - It emphasizes the importance of Biopharma/Biotech companies with innovative pipelines and performance entering a volume increase phase, including Innovent Biologics, BeiGene, and others [2][5]. - The report also points out the recovery potential for leading medical equipment companies like United Imaging Healthcare, Lepu Medical, and others [2][5]. Summary by Sections A-Shares Performance - In the second week of November 2025, the A-Shares pharmaceutical sector outperformed, with the SW Pharmaceutical and Biological index rising by 3.3% while the SHCOMP fell by 0.2% [2][30]. - The pharmaceutical commerce, chemical raw materials, and chemical preparations sub-sectors showed strong performance, with increases of 5.7%, 5.1%, and 4.4% respectively [2][30]. - Notable stock gains included GDK (+61.6%), HPGC Renmintongtai Pharmaceutical Corporation (+61.1%), and Chengda Pharmaceuticals Co., Ltd. (+58.3%) [2][30]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also outperformed, with the Hang Seng Healthcare index increasing by 6.8% and the Hong Kong Biotechnology index by 7.1% [2][31]. - In the U.S., the S&P Healthcare Select Sector rose by 3.9%, significantly outperforming the S&P 500, which only increased by 0.1% [2][32]. Valuation Metrics - As of November 14, 2025, the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 77.0% [2][15]. - The report provides earnings forecasts and valuation metrics for various companies, indicating expected growth rates and price-to-earnings ratios for the coming years [6][7].

截至11月17日收盘，创新药概念下跌1.72%，位居概念板块跌幅榜前列，板块内，科兴制药、舒泰神、 昂利康等跌幅居前，股价上涨的有33只，涨幅居前的有富祥药业、海南海药、百花医药等，分别上涨 12.14%、10.04%、8.63%。 | 603858 | 步长制药 | -2.89 | 0.96 | -906.39 | | --- | --- | --- | --- | --- | | 301075 | 多瑞医药 | -2.17 | 1.99 | -894.32 | | 301408 | 华人健康 | -2.92 | 22.50 | -887.82 | | 600479 | 千金药业 | -1.90 | 1.87 | -871.50 | | 000597 | 东北制药 | -1.54 | 1.20 | -835.15 | | 002099 | 海翔药业 | 1.1 1 | 1.30 | -831.28 | | 301333 | 诺思格 | -1.53 | 3.36 | -788.71 | | 300575 | 中旗股份 | 0.15 | 2.31 | -781.84 | | 300026 | 红日药业 | -1 ...

Group 1 - The weight loss drug concept sector declined by 1.87%, ranking among the top declines in concept sectors, with *ST San Sheng hitting the daily limit down [1][2] - Among the weight loss drug stocks, Baohua Pharmaceutical, Zhongsheng Pharmaceutical, and Lanxiao Technology saw increases of 8.63%, 2.00%, and 1.36% respectively [1][4] - The weight loss drug sector experienced a net outflow of 1.972 billion yuan, with 47 stocks seeing net outflows, and 7 stocks with outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock in the weight loss drug sector was Zhongsheng Pharmaceutical, with a net outflow of 716.46 million yuan [2][3] - Other notable net outflows included Heng Rui Pharmaceutical (236.06 million yuan), Han Yu Pharmaceutical (124.39 million yuan), and Fosun Pharmaceutical (104.04 million yuan) [2][3] - Stocks with the highest net inflows included Baohua Pharmaceutical (79.05 million yuan), Boji Pharmaceutical (13.46 million yuan), and Tainkang (10.27 million yuan) [2][4]

Group 1 - The cell immunotherapy sector experienced a decline of 1.87%, ranking among the top losers in the concept sector, with companies like Shutaishen, Jimin Health, and Puris leading the declines [1][2] - Among the concept stocks, Baohua Pharmaceutical, ST Zhongzhu, and Laimei Pharmaceutical saw the highest gains, with increases of 8.63%, 4.80%, and 0.93% respectively [1][3] - The cell immunotherapy sector faced a net outflow of 1.658 billion yuan, with 54 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 50 million yuan [1][2] Group 2 - The top net outflow stocks in the cell immunotherapy sector included Shutaishen with a net outflow of 284.46 million yuan, followed by Hengrui Medicine, Hanyu Pharmaceutical, and Fosun Pharmaceutical with outflows of 236.06 million yuan, 124.39 million yuan, and 104.04 million yuan respectively [1][2] - Conversely, the stocks with the highest net inflows included Baohua Pharmaceutical, Boji Pharmaceutical, and Yuekang Pharmaceutical, with inflows of 79.05 million yuan, 13.46 million yuan, and 4.04 million yuan respectively [1][3] - The trading volume for Shutaishen was 12.35%, indicating significant trading activity despite the decline in stock price [2][3]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets, targeting breast cancer treatment [1] Group 1: Product Development - HRS-6209 is a novel selective CDK4 inhibitor that effectively inhibits the CDK4/cyclinD complex and downstream signaling, inducing tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors [1] - HRS-6209 has improved selectivity for the CDK6/cyclinD3 signaling pathway compared to CDK4/6 inhibitors, potentially reducing blood toxicity associated with CDK4/6 inhibitors [1] - The total R&D investment for HRS-6209 has reached approximately 80.37 million yuan [1] Group 2: Market Position - There are currently no similar products approved for market in both domestic and international markets for HRS-6209 [1] - HRS-2189 is a new KAT6 inhibitor that regulates downstream oncogene expression by inhibiting histone lysine acetylation, also aimed at treating advanced malignant tumors [1] - The total R&D investment for HRS-2189 has reached approximately 49 million yuan [1] - There are currently no approved drugs targeting the same pathway as HRS-2189 in both domestic and international markets [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Tegilide Injection, marking a significant step in the development of China's first independently developed class 1 opioid analgesic [1] Company Summary - Heng Rui Medicine's Fumaric Acid Tegilide Injection is a μ-opioid receptor (MOR) biased small molecule agonist, expected to be approved for domestic market launch in January 2024 [1] - The company has invested approximately 199.99 million yuan in the research and development of Fumaric Acid Tegilide Injection to date [1] Industry Summary - Fumaric Acid Tegilide Injection is positioned as a novel opioid analgesic in China, with a similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, already approved in the U.S. in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although sales data is currently unavailable [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets, targeting breast cancer treatment [1] Group 1: Product Development - HRS-6209 is a novel selective CDK4 inhibitor that effectively inhibits the CDK4/cyclinD complex and downstream signals, inducing tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors [1] - HRS-6209 has improved selectivity for the CDK6/cyclinD3 signaling pathway compared to CDK4/6 inhibitors, potentially reducing blood toxicity associated with CDK4/6 inhibitors [1] - The total R&D investment for HRS-6209 has reached approximately 80.37 million yuan [1] Group 2: Market Position - There are currently no similar products approved for market in both domestic and international markets for HRS-6209 [1] - HRS-2189 is a new KAT6 inhibitor that regulates downstream oncogene expression by inhibiting histone lysine acetylation, also aimed at treating advanced malignant tumors [1] - The total R&D investment for HRS-2189 has reached approximately 49 million yuan [1] - There are currently no approved drugs targeting the same pathway as HRS-2189 in both domestic and international markets [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Targinine Injection, marking a significant step in the development of innovative pain relief medications in China [1] Group 1: Company Developments - The company will soon initiate clinical trials for Fumaric Acid Targinine Injection, which is a μ-opioid receptor (MOR) biased small molecule agonist [1] - This product is set to be approved for market launch in China in January 2024, representing the first domestically developed Class 1 opioid analgesic innovation [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于富马酸泰吉利定注射液的《药 物临床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 一、药品的基本情况 药品名称：富马酸泰吉利定注射液 二、药品的其他情况 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-181 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 剂 型：注射剂 申请事项：临床试验 受 理 号：CXHL2500912、CXHL2500913 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 28 日受理的富马酸泰吉利定注射液临床试验申请符合药品注册的有关要 求，同意本品开展用于重症监护患者机械通气时的镇痛的临床试验。 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 些不确定性因素的 ...